| Outcome Measures: |
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12, HbA1c is a blood test to measure blood sugar control over the prior 3-month period. The last observation carried forward (LOCF) method was used: the last observed post-baseline measurements prior to Week 12 carried forward for participants with no available Week 12 values. Participants were summarized according to the actual treatment received regardless of the allocated treatment., Baseline to Week 12|Change From Baseline in 2-hour Postprandial Serum Glucose at Week 12 Following a Standardized Meal, 2-hour postprandial serum glucose was defined as the average of serum glucose measurement at 120 minutes and 125 minutes following a standardized meal. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment., Baseline to Week 12|Change From Baseline in Fasting Serum Glucose at Week 12, Serum glucose was measured following an overnight fast. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment., Baseline to Week 12 |
|
| Locations: |
AMCR Institute, Escondido, California, 92026, United States|National Research Institute (NRI), Los Angeles, California, 90057, United States|SeaView Research Inc., Miami, Florida, 33126, United States|Orlando Clinical Research Center (OCRC), Orlando, Florida, 32809, United States|Midwest Institute For Clinical Research Inc. (MICR), Indianapolis, Indiana, 46260, United States|Vince and Associates Clinical Research, Overland Park, Kansas, 66212, United States|L-MARC Research Center, Louisville, Kentucky, 40213, United States|Rochester Clinical Research (RCR), Rochester, New York, 14609, United States|Cetero Research, San Antonio, Texas, 78229, United States
|
